<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20350302</article-id><article-id pub-id-type="pmc">2876785</article-id><article-id pub-id-type="publisher-id">alzrt30</article-id><article-id pub-id-type="doi">10.1186/alzrt30</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>A novel A&#x003b2; isoform pattern in CSF reflects &#x003b3;-secretase inhibition in Alzheimer disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Portelius</surname><given-names>Erik</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>erik.portelius@neuro.gu.se</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Dean</surname><given-names>Robert A</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>DEAN_ROBERT_A@LILLY.COM</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Gustavsson</surname><given-names>Mikael K</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mikael.ke.gustavsson@vgregion.se</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Andreasson</surname><given-names>Ulf</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ulf.andreasson@neuro.gu.se</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Zetterberg</surname><given-names>Henrik</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>henrik.zetterberg@clinchem.gu.se</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Siemers</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>SIEMERS_ERIC_R@LILLY.COM</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Blennow</surname><given-names>Kaj</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kaj.blennow@neuro.gu.se</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Molndal, SE-431 80, Sweden</aff><aff id="I2"><label>2</label>Translational Medicine, Eli Lilly and Company, Lilly Corporate Headquarters, Indianapolis, IN 46285, USA</aff><aff id="I3"><label>3</label>Global Alzheimer's Disease Research Team, Eli Lilly and Company, Lilly Corporate Headquarters, Indianapolis, IN 46285, USA</aff><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>29</day><month>3</month><year>2010</year></pub-date><volume>2</volume><issue>2</issue><fpage>7</fpage><lpage>7</lpage><history><date date-type="received"><day>12</day><month>1</month><year>2010</year></date><date date-type="rev-recd"><day>12</day><month>3</month><year>2010</year></date><date date-type="accepted"><day>29</day><month>3</month><year>2010</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2010 Portelius et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>Portelius et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://alzres.com/content/2/2/7"/><abstract><sec><title>Introduction</title><p>LY450139 (semagacestat) inhibits &#x003b3;-secretase, a key enzyme for generation of amyloid &#x003b2; (A&#x003b2;), the peptide deposited in plaques in Alzheimer disease (AD). Previous data have shown that LY450139 lowers plasma A&#x003b2;, but has no clear effect on A&#x003b2;1-40 or A&#x003b2;1-42 levels in cerebrospinal fluid (CSF). By using targeted proteomics techniques, we recently identified several shorter A&#x003b2; isoforms, such as A&#x003b2;1-16, that in experimental settings increase during &#x003b3;-secretase inhibitor treatment, and thus may serve as sensitive biochemical indices of the treatment effect. Here, we test the hypothesis that these shorter A&#x003b2; isoforms may be biomarkers of &#x003b3;-secretase inhibitor treatment in clinical trials.</p></sec><sec><title>Methods</title><p>In a phase II clinical trial, 35 individuals with mild to moderate AD were randomized to placebo (<italic>n</italic> = 10) or LY450139 (100 mg (<italic>n</italic> = 15) or 140 mg (<italic>n</italic> = 10)) and underwent lumbar puncture at baseline and after 14 weeks of treatment. The CSF A&#x003b2; isoform pattern was analyzed with immunoprecipitation combined with MALDI-TOF mass spectrometry.</p></sec><sec><title>Results</title><p>The CSF levels of A&#x003b2;1-14, A&#x003b2;1-15, and A&#x003b2;1-16 showed a dose-dependent increase by 57% and 74%, 21% and 35%, and 30% and 67%, respectively in the 100-mg and 140-mg treatment groups. A&#x003b2;1-40 and A&#x003b2;1-42 were unaffected by treatment.</p></sec><sec><title>Conclusions</title><p>CSF A&#x003b2;1-14, A&#x003b2;1-15, and A&#x003b2;1-16 increase during &#x003b3;-secretase inhibitor treatment in AD, even at doses that do not affect A&#x003b2;1-42 or A&#x003b2;1-40, probably because of increased substrate availability of the C99 APP stub (APP &#x003b2;-CTF) induced by &#x003b3;-secretase inhibition. These A&#x003b2; isoforms may be novel sensitive biomarkers to monitor the biochemical effect in clinical trials.</p></sec><sec><title>Trial registration</title><p>Clinical Trials.gov NCT00244322</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Accumulation of amyloid &#x003b2; (A&#x003b2;) peptides in senile plaques in the cerebral cortex is an early event in the pathogenesis of Alzheimer disease (AD) [<xref ref-type="bibr" rid="B1">1</xref>]. The longest isoform of A&#x003b2;, consisting of 42 amino acids (A&#x003b2;1-42), is produced from amyloid precursor protein (APP) by sequential cleavage by &#x003b2;- and &#x003b3;-secretase in the amyloidogenic APP-processing pathway (Figure <xref ref-type="fig" rid="F1">1A</xref>) [<xref ref-type="bibr" rid="B2">2</xref>]. &#x003b2;-Secretase activity originates from an integral membrane aspartyl protease encoded by the &#x003b2;-site APP-cleaving enzyme 1 gene (<italic>BACE1</italic>) [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B6">6</xref>] whereas &#x003b3;-secretase is an intramembrane-cleaving complex composed of at least four essential subunits with the presenilin (PS1 or PS2) proteins at its enzymatic core [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. &#x003b3;-Secretase, which is one of the top targets for developing AD therapeutics with disease-modifying effects, cleaves the transmembrane region of APP to produce A&#x003b2; of variable length [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>], with A&#x003b2;1-40 being the most abundant isoform, whereas A&#x003b2;1-42 is most prone to aggregation [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Schematic drawing of APP and generation of A&#x003b2; isoforms</bold>. The 17-amino acid signal peptide is indicated at the N-terminus. A single membrane-spanning domain is located at amino acids 700-723 in the longest APP isoform (APP770). <bold>(a)</bold> In the amyloidogenic pathway, &#x003b2;-secretase cleaves after residue 671, generating &#x003b2;-sAPP, which is secreted, and a C-terminal fragment (&#x003b2;-CTF or C99), which is retained in the membrane. The &#x003b2;-CTF fragment can undergo further cleavage by &#x003b3;-secretase to release A&#x003b2; isoforms. <bold>(b)</bold> In another pathway, APP is first cleaved by &#x003b2;-secretase, but after this, by &#x003b1;-secretase, thus generating the shorter isoforms A&#x003b2;1-14, A&#x003b2;1-15, and A&#x003b2;-16. In another described nonamyloidogenic pathway, &#x003b1;-secretase cleaves between amino acids 16 and 17 in the A&#x003b2; sequence generating &#x003b1;-sAPP, followed by &#x003b3;-secretase cleavages, generating a fragment called p3 (A&#x003b2;17-40/42). This 3-kDa fragment has been isolated from cell-culture medium [<xref ref-type="bibr" rid="B29">29</xref>] and in brains from AD patients [<xref ref-type="bibr" rid="B30">30</xref>]. However, the fragment has never been detected in human CSF. AICD, APP intracellular domain; APP, amyloid precursor protein; A&#x003b2;, amyloid &#x003b2;; sAPP, soluble amyloid precursor protein.</p></caption><graphic xlink:href="alzrt30-1"/></fig><p>The main focus of using disease-modifying drugs is to inhibit brain A&#x003b2; production and aggregation and to increase A&#x003b2; clearance from the brain. Several drug candidates, including &#x003b2;-secretase and &#x003b3;-secretase inhibitors or A&#x003b2; immunotherapy, are being evaluated in different phases in clinical trials. However, in a slowly progressive disorder like AD, evaluation of the clinical effect of a disease-modifying drug by using rating scales requires large patient numbers and extended treatment periods. This type of drug cannot be expected to have any early effect on symptoms, but instead may show a less-pronounced decline in cognitive function over years. Thus, a great need exists for biomarkers to identify and monitor the biochemical effect of disease-modifying drugs in AD clinical trials. Such biomarker data providing evidence directly in patients with AD that the drug has the predicted mechanism of action may be valuable for making a go/no-go decision for large and expensive Phase II or III clinical trials.</p><p>In animal studies, a decrease in soluble A&#x003b2; levels and A&#x003b2; accumulation has been reported in response to &#x003b3;-secretase inhibition [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. Recently, in a human clinical trial, it was shown, by using enzyme-linked immunosorbent assay (ELISA), that the &#x003b3;-secretase inhibitor LY450139 reduces the concentration of A&#x003b2;1-40 and A&#x003b2;1-42 in human plasma in a dose-dependent manner, whereas a significant decrease in human cerebrospinal fluid (CSF) A&#x003b2; levels was not detected [<xref ref-type="bibr" rid="B19">19</xref>]. However, by using a stable isotope-labeling kinetic (SILK) method, which can be used to measure central nervous system (CNS) production and clearance rates of total A&#x003b2; in the CSF of humans [<xref ref-type="bibr" rid="B20">20</xref>], it was shown that LY450139 significantly decreased A&#x003b2; production without affecting A&#x003b2; clearance in the CNS [<xref ref-type="bibr" rid="B21">21</xref>].</p><p>We recently identified a set of 18 N- and C-terminally truncated A&#x003b2; peptides in human CSF by using immunoprecipitation-mass spectrometry (IP-MS) and showed that CSF A&#x003b2;1-16 may be a novel positive biomarker for AD that was elevated in AD patients [<xref ref-type="bibr" rid="B22">22</xref>]. This novel biomarker for AD is generated through a previously unrecognized metabolic pathway by concerted &#x003b2;- and &#x003b1;-secretase cleavage of APP (Figure <xref ref-type="fig" rid="F1">1B</xref>) [<xref ref-type="bibr" rid="B23">23</xref>]. Further, the relative level of A&#x003b2;1-16, along with A&#x003b2;1-14 and A&#x003b2;1-15, has previously been shown to be elevated in cell media and in CSF from mice in response to &#x003b3;-secretase inhibitor treatment [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>], suggesting that these shorter A&#x003b2; isoforms may be sensitive biomarkers for &#x003b3;-secretase inhibitor treatment. Here, we tested the hypothesis that treatment of AD patients with the &#x003b3;-secretase inhibitor LY450139 can be monitored by increased CSF levels of A&#x003b2;1-14, A&#x003b2;1-15, and A&#x003b2;1-16.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Study participants and sample collection</title><p>The study cohort and clinical procedures have been described before in detail [<xref ref-type="bibr" rid="B19">19</xref>]. In brief, 51 patients were enrolled at six academic research centers between October 1, 2005, and December 31, 2006 (Figure <xref ref-type="fig" rid="F2">2a</xref>). The protocol was reviewed and approved by the institutional review board at each participating site. All research participants and caregivers gave written informed consent. Of the 51 patients enrolled in the study, CSF samples from 35 patients were available for analysis by IP-MS. See Table <xref ref-type="table" rid="T1">1</xref> for demographic data.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Data flowchart for the trial</bold>. <bold>(a)</bold> The intention-to-treat analyses included all 51 patients originally randomized, including all subsequent dropouts. Of the 51 patients, 35 were analyzed by using IP-MS. <bold>(b) </bold>Study design.</p></caption><graphic xlink:href="alzrt30-2"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Participant characteristics at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">Placebo</th><th align="center">LY450139, 100 mg</th><th align="center">LY450139, 140 mg</th></tr><tr><th align="left">Characteristic</th><th align="center">(<italic>n</italic> = 10)</th><th align="center">(<italic>n</italic> = 15)</th><th align="center">(<italic>n</italic> = 10)</th></tr></thead><tbody><tr><td align="left">Demographics</td><td/><td/><td/></tr><tr><td align="left">Age, mean (SD, years)</td><td align="center">69.1 (8.81)</td><td align="center">72.4 (8.13)</td><td align="center">68.8 (9.02)</td></tr><tr><td align="left">Female sex, number (%)</td><td align="center">5 (50)</td><td align="center">10 (66.6)</td><td align="center">4 (40)</td></tr><tr><td align="left">APOE e4 carriers, number (%)</td><td align="center">8 of 10 (80)</td><td align="center">11 of 13 (84.6)</td><td align="center">7 of 9 (77.8)</td></tr><tr><td align="left">Clinical scores, mean (SD)</td><td/><td/><td/></tr><tr><td align="left">MMSE</td><td align="center">18.3 (4.0)</td><td align="center">22 (3.6)</td><td align="center">24.9 (1.4)</td></tr><tr><td align="left">ADCS-ADL</td><td align="center">61.9 (7.3)</td><td align="center">67.7 (8.4)</td><td align="center">70.6 (7.8)</td></tr><tr><td align="left">ADAS-Cog 11</td><td align="center">26.9 (10.0)</td><td align="center">19.9 (6.3)</td><td align="center">17.9 (5.8)</td></tr></tbody></table><table-wrap-foot><p>ADAS-Cog 11, Alzheimer's Disease Assessment Scale Cognitive Subscale; ADCS-ADL, Alzheimer's Disease Cooperative Study Activities of Daily Living Scale; APOE, apolipoprotein E; MMSE, Mini-Mental State Examination.</p></table-wrap-foot></table-wrap><p>Participants were 50 years or older and diagnosed as having probable AD, as defined by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) criteria [<xref ref-type="bibr" rid="B25">25</xref>]. Individuals receiving stable doses of cholinesterase-inhibitor drugs or memantine were included. The trial was a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study (Figure <xref ref-type="fig" rid="F2">2a</xref>). Participants were randomized to receive LY450139 or placebo by using a 2:1 randomization scheme through a telephone-based interactive voice-response system (Figure <xref ref-type="fig" rid="F2">2b</xref>). Patients randomized to the LY450139 groups received 60 mg/d for 2 weeks, and then 100 mg/d for the next 6 weeks. At 8 weeks, the treatment arm was randomized again to receive 6 additional weeks of treatment at 100 or 140 mg/d.</p><p>The CSF samples were collected into polypropylene tubes by means of a lumbar puncture at baseline and approximately 6 hours after the administration of the last dose of LY450139 at week 14.</p></sec><sec><title>APP measurements</title><p>CSF concentrations of &#x003b1;-secretase-cleaved soluble APP (&#x003b1;-sAPP) and &#x003b2;-secretase-cleaved soluble APP (&#x003b2;-sAPP) were determined by using the MSD sAPP&#x003b1;/sAPP&#x003b2; multiplex assay, as described by the manufacturer (Meso Scale Discovery, Gaithersburg, MD, USA). This assay uses the 6E10 antibody to capture &#x003b1;-sAPP and a neoepitope-specific antibody to capture &#x003b2;-sAPP. Both isoforms are detected by the SULFO-TAG-labeled anti-APP antibody p2-1.</p></sec><sec><title>IP-MS</title><p>IP was combined with matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS for analyzing the A&#x003b2; isoform pattern in a single analysis. The IP-MS was conducted as described before [<xref ref-type="bibr" rid="B26">26</xref>]. In brief, 8 &#x003bc;g of the monoclonal antibody 6E10 (A&#x003b2; epitope 4-9; Signet Laboratories, Inc., Dedham, MA, USA) was added to 50 &#x003bc;l Dynabeads M-280 (Dynal) sheep anti-mouse and left overnight on a rocking platform (+4&#x000b0;C). The IP was conducted overnight (+4&#x000b0;C) on 940 &#x003bc;l CSF, to which 10 &#x003bc;l 2.5% Tween-20 (Bio-Rad Laboratories, Inc.) had been added. The beads/CSF solution (total volume, 1 ml) was transferred to a KingFisher magnetic particle processor (polypropylene tubes; Thermo Scientific) for washing and elution in a five-step procedure. The collected supernatant was dried in a vacuum centrifuge and redissolved in 5 &#x003bc;l 0.1% formic acid in 20% acetonitrile.</p><p>The samples were analyzed with MALDI-TOFMS (Autoflex, Bruker Daltonics, Bremen, Germany) operating in reflector mode. The acquired MS data were analyzed by the software Medicwave Bioinformatics Suite (MBS) by using the immunoprecipitation for MALDI (IPM) module (MedicWave, Halmstad, Sweden) for automatic processing of the all spectra. In brief, after internal calibration, baseline subtraction, and smoothing, the peaks for each spectrum were integrated with the integration limits -2 to +5 m/z relative to the monoisotopic peak. Before the statistical analysis, the peak areas were normalized to the sum of the integrated peaks, duplicated samples were averaged, and the relative changes compared with baseline values were calculated, as described previously [<xref ref-type="bibr" rid="B22">22</xref>].</p><p>Group differences were analyzed by using the Kruskal-Wallis test, and in case of significance (<italic>P</italic> &#x0003c; 0.05), followed by Mann-Whitney test to identify the differences.</p></sec></sec><sec><title>Results</title><p>Representative CSF A&#x003b2; isoform mass spectra from an AD patient before treatment and after 14 weeks on the high dosage of the &#x003b3;-secretase inhibitor LY450139 are shown in Figure <xref ref-type="fig" rid="F3">3a</xref>. The treatment greatly increased the mass spectrometric signal for A&#x003b2;1-14, A&#x003b2;1-15, and A&#x003b2;1-16, whereas the mass spectrometric signal corresponding to A&#x003b2;1-34 decreased as a response to treatment (Kruskal-Wallis test, <italic>P </italic>= 0.009, 0.01, 0.05, and 0.000041, respectively). The other A&#x003b2; isoforms reproducibly detected in all spectra (A&#x003b2;1-17, A&#x003b2;1-18, A&#x003b2;1-19, A&#x003b2;1-33, A&#x003b2;1-37, A&#x003b2;1-38, A&#x003b2;1-40, and A&#x003b2;1-42) did not differ significantly in intensity before and after treatment. The levels of the A&#x003b2; isoforms A&#x003b2;1-13 and A&#x003b2;1-20 were low, were not detected in all samples, and were therefore omitted from further analysis. The mass-to-charge (m/z) ratio of A&#x003b2;1-18 [M + H]<sup>+ </sup>is almost identical to the m/z of the second charge state of A&#x003b2;1-40 [M + 2H]<sup>2+ </sup>and therefore difficult to quantify; it was excluded from further analysis.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Representative mass spectra</bold>. <bold>(a) </bold>Representative mass spectra from an AD patient displaying the A&#x003b2;-isoform pattern before treatment (red spectra) and after treatment with 140 mg of the &#x003b3;-secretase inhibitor LY450139 (blue spectra). The mass spectrometric signal of A&#x003b2;1-14/15/16 increased, whereas A&#x003b2;1-34 decreased. The longer isoforms, including A&#x003b2;1-17, A&#x003b2;1-40, and A&#x003b2;1-42, were unaffected by the treatment. The relative change as a response to treatment is displayed for <bold>(b) </bold>all A&#x003b2; isoforms detected in all samples and <bold>(c) </bold>&#x003b1;-sAPP and &#x003b2;-sAPP. The error bars represent standard errors of the mean.</p></caption><graphic xlink:href="alzrt30-3"/></fig><p>In the 100-mg group, after drug administration at week 14, the CSF levels of A&#x003b2;1-14, A&#x003b2;1-15, and A&#x003b2;1-16 were significantly increased by a mean of 57%, 21%, and 30%, respectively, whereas A&#x003b2;1-34 decreased 39% (see Figure <xref ref-type="fig" rid="F3">3b</xref> and Table <xref ref-type="table" rid="T2">2</xref>) compared with study baseline. The same result was seen in the 140-mg group, A&#x003b2;1-14, A&#x003b2;1-15 and A&#x003b2;1-16 were increased by means of 74%, 35%, and 67%, respectively, whereas A&#x003b2;1-34 decreased 37% (Table <xref ref-type="table" rid="T2">2</xref>). No statistically significant changes were seen for any other A&#x003b2; isoforms detected. &#x003b1;-sAPP showed a tendency to increased levels (13%) in the 140-mg group, whereas &#x003b2;-sAPP was unaffected by all the treatments (Figure <xref ref-type="fig" rid="F3">3c</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Summary of Mann-Whitney test for peptides</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">Placebo vs. 100 mg</th><th align="center">Placebo vs. 140 mg</th><th align="center">100 mg vs. 140 mg</th></tr></thead><tbody><tr><td align="left">A&#x003b2;1-14</td><td align="center">0.002</td><td align="center">0.03</td><td align="center">0.58</td></tr><tr><td align="left">A&#x003b2;1-15</td><td align="center">0.04</td><td align="center">0.004</td><td align="center">0.17</td></tr><tr><td align="left">A&#x003b2;1-16</td><td align="center">0.05</td><td align="center">0.003</td><td align="center">0.04</td></tr><tr><td align="left">A&#x003b2;1-34</td><td align="center">0.00005</td><td align="center">0.0002</td><td align="center">0.82</td></tr></tbody></table><table-wrap-foot><p>Kruskal-Wallace test, <italic>P </italic>&#x0003c; 0.05.</p></table-wrap-foot></table-wrap></sec><sec><title>Discussion</title><p>Intense multidisciplinary research efforts during the last decades have provided detailed knowledge on the molecular pathogenesis of AD, which has been translated into novel promising therapies with putative disease-modifying effects. Several promising drug candidates, such as A&#x003b2; immunotherapy and secretase inhibitors, are now being tested in clinical trials. However, because the predicted clinical effect of this type of disease-modifying drugs is a less-pronounced slope in the rate of cognitive deterioration, without any early symptomatologic effect, very large clinical trials with extended treatment periods will be needed to identify a beneficial clinical effect by using rating scales. Thus, biomarker evidence from smaller short-term clinical trials that the drug has the predicted biochemical mode of action directly in patients with AD would be valuable for making a go/no-go decision for expensive Phase III clinical trials. Thus, a great need exists for biomarkers to identify and monitor the biochemical effect of disease-modifying drugs in AD clinical trials.</p><p>The main focus with disease-modifying drugs is to inhibit brain A&#x003b2; production and aggregation and to increase A&#x003b2; clearance from the brain. &#x003b3;-Secretase inhibitors have previously been shown to reduce A&#x003b2;1-40 and A&#x003b2;1-42 production and secretion in cells and to reduce soluble A&#x003b2; and amyloid plaque burden in mice [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. These results have made the &#x003b3;-secretase complex one of the top targets for developing AD therapeutics. Here we show that the novel A&#x003b2; isoforms A&#x003b2;1-14, A&#x003b2;1-15, and A&#x003b2;1-16, together with A&#x003b2;1-34, may serve as sensitive biomarkers for &#x003b3;-secretase inhibition by LY450139 in the CNS of AD patients.</p><p>In a previous study using ELISA measurements of CSF A&#x003b2;1-40 and A&#x003b2;1-42, the expected reduction of the peptides in response to LY450139 treatment was not found [<xref ref-type="bibr" rid="B19">19</xref>]. It was suggested that this lack of changes might be the result of a rapid transport of A&#x003b2; from CSF into plasma or that longer treatment duration may be required to identify changes [<xref ref-type="bibr" rid="B19">19</xref>]. In another study using the SILK method to examine whether an effect on A&#x003b2; production could be identified with LY450139 treatment, it was shown that A&#x003b2; production in the CNS decreased while A&#x003b2; clearance remained stable [<xref ref-type="bibr" rid="B21">21</xref>]. The lack of effect on CSF A&#x003b2;1-40 and A&#x003b2;1-42, despite the reduced A&#x003b2; production, may be because the different techniques are measuring different targets. SILK analysis of A&#x003b2; turnover requires that all A&#x003b2; isoforms are digested with trypsin before analysis, and a cleavage product consisting of A&#x003b2;17-28 is then measured by using MS [<xref ref-type="bibr" rid="B20">20</xref>]. Thus, total A&#x003b2; (that is, the mean of all of the very different A&#x003b2; isoforms that contain the A&#x003b2;17-28 sequence) is measured. This means that all longer isoforms detected in the present study (A&#x003b2;1-33, A&#x003b2;1-34, A&#x003b2;1-37, A&#x003b2;1-38, A&#x003b2;1-40, and A&#x003b2;1-42) will contribute to the mass spectrometric signal. The results presented herein suggest that the reduction in A&#x003b2;1-34, the generation of which is &#x003b3;-secretase dependent [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B27">27</xref>], may contribute to the overall reduction of A&#x003b2; detected in CSF by using the SILK method.</p><p>Previous experimental studies on certain cultured cells expressing wild-type human APP have shown that &#x003b3;-secretase inhibitor can increase in &#x003b1;- and &#x003b2;-secretase cleavage products along with the expected increase in APP C-terminal fragments (C99 APP-CTF) [<xref ref-type="bibr" rid="B28">28</xref>]. Further, recent data have shown that the levels of A&#x003b2;1-14, A&#x003b2;1-15, and A&#x003b2;1-16 are elevated in cell media and CSF from transgenic mice treated with &#x003b3;-secretase inhibitors and that these shorter isoforms are derived from concerted cleavages of APP by &#x003b2;- and &#x003b1;-secretase, thus reflecting a third metabolic pathway for APP [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. Data in this study suggest that these shorter A&#x003b2; isoforms may be sensitive novel biomarkers for &#x003b3;-secretase inhibitor treatment, even at doses that do no affect the CSF levels of A&#x003b2;1-40 or A&#x003b2;1-42. The increased levels of the isoforms detected after &#x003b3;-secretase inhibitor treatment might be explained by an increased amount of substrate (that is, &#x003b2;-CTF or C99) (Figure <xref ref-type="fig" rid="F1">1</xref>), for &#x003b1;-secretase, after APP is cleaved by &#x003b2;-secretase.</p><p>Here we verify these findings directly in living AD patients (that is, a major increase of the shorter isoforms and a slight increase of &#x003b1;-sAPP, in CSF from AD patients treated with a &#x003b3;-secretase inhibitor). The unchanged CSF levels of A&#x003b2;1-40 and A&#x003b2;1-42 are in agreement with previous studies [<xref ref-type="bibr" rid="B19">19</xref>] and suggest that these markers are less sensitive to detect &#x003b3;-secretase inhibition as compared with A&#x003b2;1-14, A&#x003b2;1-15, and A&#x003b2;1-16, possibly because they may be influenced by other factors, such as brain amyloid load and/or A&#x003b2; oligomerization or that they are present at higher levels in CSF and that higher doses are needed to detect effects on these biomarkers in AD patients. Unchanged &#x003b2;-sAPP levels and only slightly elevated &#x003b1;-sAPP levels suggest that &#x003b3;-secretase inhibition does not result in any major change in the release of these APP fragments to the CSF. It is at this stage unclear whether these fragments are degraded further or if they simply are present in such high concentrations in the CSF that a very high &#x003b3;-secretase inhibitor dose is needed to detect an effect on CSF &#x003b1;-sAPP and &#x003b2;-sAPP levels.</p></sec><sec><title>Conclusions</title><p>This study suggests that A&#x003b2;1-14, A&#x003b2;1-15, and A&#x003b2;1-16 are positive and very sensitive biomarkers for &#x003b3;-secretase inhibition and can be used to detect biochemical effects on APP processing in AD patients treated with LY450139. Long-term clinical trials are needed to reveal whether these biomarkers predict a beneficial clinical treatment effect.</p></sec><sec><title>Abbreviations</title><p>A&#x003b2;: Amyloid &#x003b2;; AD: Alzheimer disease; APP: amyloid precursor protein; BACE1: &#x003b2;-site APP-cleaving enzyme 1 gene; CNS: central nervous system; CSF: cerebrospinal fluid; ELISA: enzyme-linked immunosorbent assay; IP-MS: immunoprecipitation mass spectrometry; MALDI-TOF: matrix-assisted laser desorption/ionization time-of-flight; NINCDS-ADRDA: Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association; PS: presenilin; &#x003b1;-sAPP: &#x003b1;-secretase cleaved soluble APP; &#x003b2;-sAPP: &#x003b2;-secretase cleaved soluble APP; SILK: stable isotope-labeling kinetic.</p></sec><sec><title>Competing interests</title><p>The clinical trial part of the study was sponsored by Eli Lilly &#x00026; Company. For the biochemistry part, the sponsors had no role in study design, data collection, data analysis, data interpretation, or writing of the article. Dr. Erik Portelius, BSc, Mikael Gustavsson, Dr. Ulf Andreasson, and Henrik Zetterberg, MD, declare that they have no competing interests. Kaj Blennow, MD, has on one occasion served on an advisory board for Eli Lilly &#x00026; Company. Robert A. Dean, MD, and Eric Siemers, MD, are employees of Eli Lilly &#x00026; Company and therefore are stockholders.</p></sec><sec><title>Authors' contributions</title><p>EP planned the experimental design, analyzed and interpreted data, and drafted the manuscript. RAD designed the clinical trial. MG acquired data. UA analyzed and interpreted data. HZ analyzed and interpreted data. ES designed the clinical trial. KB planned the experimental design and analyzed and interpreted data. All authors reviewed, revised, and agreed on the submitted version.</p></sec></body><back><sec><title>Acknowledgements</title><p>This work was supported by grants from the Swedish Research Council (projects 2006-6227, 2006-2740, 2006-3505, and 14002), the Alzheimer's Association (NIRG-08-90356), cNEUPRO, the Royal Swedish Academy of Sciences, the Sahlgrenska University Hospital, Swedish Brain Power, Stiftelsen Gamla Tj&#x000e4;narinnor, and Alzheimer Foundation, Sweden.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>de Leon</surname><given-names>MJ</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><article-title>Alzheimer's disease</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>387</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)69113-7</pub-id><pub-id pub-id-type="pmid">16876668</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Andersson</surname><given-names>ME</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><article-title>Aspects of beta-amyloid as a biomarker for Alzheimer's disease</article-title><source>Biomarkers Med</source><year>2007</year><volume>1</volume><fpage>59</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.2217/17520363.1.1.59</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Hussain</surname><given-names>I</given-names></name><name><surname>Powell</surname><given-names>D</given-names></name><name><surname>Howlett</surname><given-names>DR</given-names></name><name><surname>Tew</surname><given-names>DG</given-names></name><name><surname>Meek</surname><given-names>TD</given-names></name><name><surname>Chapman</surname><given-names>C</given-names></name><name><surname>Gloger</surname><given-names>IS</given-names></name><name><surname>Murphy</surname><given-names>KE</given-names></name><name><surname>Southan</surname><given-names>CD</given-names></name><name><surname>Ryan</surname><given-names>DM</given-names></name><name><surname>Smith</surname><given-names>TS</given-names></name><name><surname>Simmons</surname><given-names>DL</given-names></name><name><surname>Walsh</surname><given-names>FS</given-names></name><name><surname>Dingwall</surname><given-names>C</given-names></name><name><surname>Christie</surname><given-names>G</given-names></name><article-title>Identification of a novel aspartic protease (Asp 2) as beta-secretase</article-title><source>Mol Cell Neurosci</source><year>1999</year><volume>14</volume><fpage>419</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1006/mcne.1999.0811</pub-id><pub-id pub-id-type="pmid">10656250</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>JP</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Basi</surname><given-names>GS</given-names></name><name><surname>Caccavello</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>D</given-names></name><name><surname>Doan</surname><given-names>M</given-names></name><name><surname>Dovey</surname><given-names>HF</given-names></name><name><surname>Frigon</surname><given-names>N</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Jacobson-Croak</surname><given-names>K</given-names></name><name><surname>Jewett</surname><given-names>N</given-names></name><name><surname>Keim</surname><given-names>P</given-names></name><name><surname>Knops</surname><given-names>J</given-names></name><name><surname>Lieberburg</surname><given-names>I</given-names></name><name><surname>Power</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name><name><surname>Tatsuno</surname><given-names>G</given-names></name><name><surname>Tung</surname><given-names>J</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Suomensaari</surname><given-names>SM</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Walker</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>McConlogue</surname><given-names>L</given-names></name><name><surname>John</surname><given-names>V</given-names></name><article-title>Purification and cloning of amyloid precursor protein beta-secretase from human brain</article-title><source>Nature</source><year>1999</year><volume>402</volume><fpage>537</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1038/990114</pub-id><pub-id pub-id-type="pmid">10591214</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Vassar</surname><given-names>R</given-names></name><name><surname>Bennett</surname><given-names>BD</given-names></name><name><surname>Babu-Khan</surname><given-names>S</given-names></name><name><surname>Kahn</surname><given-names>S</given-names></name><name><surname>Mendiaz</surname><given-names>EA</given-names></name><name><surname>Denis</surname><given-names>P</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><name><surname>Ross</surname><given-names>S</given-names></name><name><surname>Amarante</surname><given-names>P</given-names></name><name><surname>Loeloff</surname><given-names>R</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Fisher</surname><given-names>S</given-names></name><name><surname>Fuller</surname><given-names>J</given-names></name><name><surname>Edenson</surname><given-names>S</given-names></name><name><surname>Lile</surname><given-names>J</given-names></name><name><surname>Jarosinski</surname><given-names>MA</given-names></name><name><surname>Biere</surname><given-names>AL</given-names></name><name><surname>Curran</surname><given-names>E</given-names></name><name><surname>Burgess</surname><given-names>T</given-names></name><name><surname>Louis</surname><given-names>JC</given-names></name><name><surname>Collins</surname><given-names>F</given-names></name><name><surname>Treanor</surname><given-names>J</given-names></name><name><surname>Rogers</surname><given-names>G</given-names></name><name><surname>Citron</surname><given-names>M</given-names></name><article-title>Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE</article-title><source>Science</source><year>1999</year><volume>286</volume><fpage>735</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1126/science.286.5440.735</pub-id><pub-id pub-id-type="pmid">10531052</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Bienkowski</surname><given-names>MJ</given-names></name><name><surname>Shuck</surname><given-names>ME</given-names></name><name><surname>Miao</surname><given-names>H</given-names></name><name><surname>Tory</surname><given-names>MC</given-names></name><name><surname>Pauley</surname><given-names>AM</given-names></name><name><surname>Brashier</surname><given-names>JR</given-names></name><name><surname>Stratman</surname><given-names>NC</given-names></name><name><surname>Mathews</surname><given-names>WR</given-names></name><name><surname>Buhl</surname><given-names>AE</given-names></name><name><surname>Carter</surname><given-names>DB</given-names></name><name><surname>Tomasselli</surname><given-names>AG</given-names></name><name><surname>Parodi</surname><given-names>LA</given-names></name><name><surname>Heinrikson</surname><given-names>RL</given-names></name><name><surname>Gurney</surname><given-names>ME</given-names></name><article-title>Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity</article-title><source>Nature</source><year>1999</year><volume>402</volume><fpage>533</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1038/990107</pub-id><pub-id pub-id-type="pmid">10591213</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Esler</surname><given-names>WP</given-names></name><name><surname>Kimberly</surname><given-names>WT</given-names></name><name><surname>Ostaszewski</surname><given-names>BL</given-names></name><name><surname>Diehl</surname><given-names>TS</given-names></name><name><surname>Moore</surname><given-names>CL</given-names></name><name><surname>Tsai</surname><given-names>JY</given-names></name><name><surname>Rahmati</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><name><surname>Wolfe</surname><given-names>MS</given-names></name><article-title>Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1</article-title><source>Nat Cell Biol</source><year>2000</year><volume>2</volume><fpage>428</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1038/35017062</pub-id><pub-id pub-id-type="pmid">10878808</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>YM</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Lai</surname><given-names>MT</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Castro</surname><given-names>JL</given-names></name><name><surname>DiMuzio-Mower</surname><given-names>J</given-names></name><name><surname>Harrison</surname><given-names>T</given-names></name><name><surname>Lellis</surname><given-names>C</given-names></name><name><surname>Nadin</surname><given-names>A</given-names></name><name><surname>Neduvelil</surname><given-names>JG</given-names></name><name><surname>Register</surname><given-names>RB</given-names></name><name><surname>Sardana</surname><given-names>MK</given-names></name><name><surname>Shearman</surname><given-names>MS</given-names></name><name><surname>Smith</surname><given-names>AL</given-names></name><name><surname>Shi</surname><given-names>XP</given-names></name><name><surname>Yin</surname><given-names>KC</given-names></name><name><surname>Shafer</surname><given-names>JA</given-names></name><name><surname>Gardell</surname><given-names>SJ</given-names></name><article-title>Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1</article-title><source>Nature</source><year>2000</year><volume>405</volume><fpage>689</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1038/35015085</pub-id><pub-id pub-id-type="pmid">10864326</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Wolfe</surname><given-names>MS</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Ostaszewski</surname><given-names>BL</given-names></name><name><surname>Diehl</surname><given-names>TS</given-names></name><name><surname>Kimberly</surname><given-names>WT</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity</article-title><source>Nature</source><year>1999</year><volume>398</volume><fpage>513</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/19077</pub-id><pub-id pub-id-type="pmid">10206644</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Beher</surname><given-names>D</given-names></name><name><surname>Wrigley</surname><given-names>JD</given-names></name><name><surname>Owens</surname><given-names>AP</given-names></name><name><surname>Shearman</surname><given-names>MS</given-names></name><article-title>Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity</article-title><source>J Neurochem</source><year>2002</year><volume>82</volume><fpage>563</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.00985.x</pub-id><pub-id pub-id-type="pmid">12153480</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Fluhrer</surname><given-names>R</given-names></name><name><surname>Multhaup</surname><given-names>G</given-names></name><name><surname>Schlicksupp</surname><given-names>A</given-names></name><name><surname>Okochi</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Lammich</surname><given-names>S</given-names></name><name><surname>Willem</surname><given-names>M</given-names></name><name><surname>Westmeyer</surname><given-names>G</given-names></name><name><surname>Bode</surname><given-names>W</given-names></name><name><surname>Walter</surname><given-names>J</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name><article-title>Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>5531</fpage><lpage>5538</lpage><pub-id pub-id-type="doi">10.1074/jbc.M211485200</pub-id><pub-id pub-id-type="pmid">12471021</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Murphy</surname><given-names>MP</given-names></name><name><surname>Hickman</surname><given-names>LJ</given-names></name><name><surname>Eckman</surname><given-names>CB</given-names></name><name><surname>Uljon</surname><given-names>SN</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Golde</surname><given-names>TE</given-names></name><article-title>gamma-Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>11914</fpage><lpage>11923</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.17.11914</pub-id><pub-id pub-id-type="pmid">10207012</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Jarrett</surname><given-names>JT</given-names></name><name><surname>Berger</surname><given-names>EP</given-names></name><name><surname>Lansbury</surname><given-names>PT</given-names><suffix>Jr</suffix></name><article-title>The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease</article-title><source>Biochemistry</source><year>1993</year><volume>32</volume><fpage>4693</fpage><lpage>4697</lpage><pub-id pub-id-type="doi">10.1021/bi00069a001</pub-id><pub-id pub-id-type="pmid">8490014</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Esselmann</surname><given-names>H</given-names></name><name><surname>Bibl</surname><given-names>M</given-names></name><name><surname>Smirnov</surname><given-names>A</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>Paul</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>B</given-names></name><name><surname>Klafki</surname><given-names>HW</given-names></name><name><surname>Maler</surname><given-names>M</given-names></name><name><surname>Dyrks</surname><given-names>T</given-names></name><name><surname>Bienert</surname><given-names>M</given-names></name><name><surname>Beyermann</surname><given-names>M</given-names></name><name><surname>R&#x000fc;ther</surname><given-names>E</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name><article-title>Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation</article-title><source>J Neurochem</source><year>2002</year><volume>81</volume><fpage>481</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.00818.x</pub-id><pub-id pub-id-type="pmid">12065657</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Best</surname><given-names>JD</given-names></name><name><surname>Smith</surname><given-names>DW</given-names></name><name><surname>Reilly</surname><given-names>MA</given-names></name><name><surname>O'Donnell</surname><given-names>R</given-names></name><name><surname>Lewis</surname><given-names>HD</given-names></name><name><surname>Ellis</surname><given-names>S</given-names></name><name><surname>Wilkie</surname><given-names>N</given-names></name><name><surname>Rosahl</surname><given-names>TW</given-names></name><name><surname>Laroque</surname><given-names>PA</given-names></name><name><surname>Boussiquet-Leroux</surname><given-names>C</given-names></name><name><surname>Churcher</surname><given-names>I</given-names></name><name><surname>Atack</surname><given-names>JR</given-names></name><name><surname>Harrison</surname><given-names>T</given-names></name><name><surname>Shearman</surname><given-names>MS</given-names></name><article-title>The novel gamma secretase inhibitor <italic>N </italic>-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse</article-title><source>J Pharmacol Exp Ther</source><year>2007</year><volume>320</volume><fpage>552</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1124/jpet.106.114330</pub-id><pub-id pub-id-type="pmid">17099072</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Cirrito</surname><given-names>JR</given-names></name><name><surname>May</surname><given-names>PC</given-names></name><name><surname>O'Dell</surname><given-names>MA</given-names></name><name><surname>Taylor</surname><given-names>JW</given-names></name><name><surname>Parsadanian</surname><given-names>M</given-names></name><name><surname>Cramer</surname><given-names>JW</given-names></name><name><surname>Audia</surname><given-names>JE</given-names></name><name><surname>Nissen</surname><given-names>JS</given-names></name><name><surname>Bales</surname><given-names>KR</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>DeMattos</surname><given-names>RB</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><article-title>In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life</article-title><source>J Neurosci</source><year>2003</year><volume>23</volume><fpage>8844</fpage><lpage>8853</lpage><pub-id pub-id-type="pmid">14523085</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Dovey</surname><given-names>HF</given-names></name><name><surname>John</surname><given-names>V</given-names></name><name><surname>Anderson</surname><given-names>JP</given-names></name><name><surname>Chen</surname><given-names>LZ</given-names></name><name><surname>de Saint Andrieu</surname><given-names>P</given-names></name><name><surname>Fang</surname><given-names>LY</given-names></name><name><surname>Freedman</surname><given-names>SB</given-names></name><name><surname>Folmer</surname><given-names>B</given-names></name><name><surname>Goldbach</surname><given-names>E</given-names></name><name><surname>Holsztynska</surname><given-names>EJ</given-names></name><name><surname>Hu</surname><given-names>KL</given-names></name><name><surname>Johnson-Wood</surname><given-names>KL</given-names></name><name><surname>Kennedy</surname><given-names>SL</given-names></name><name><surname>Kholodenko</surname><given-names>D</given-names></name><name><surname>Knops</surname><given-names>JE</given-names></name><name><surname>Latimer</surname><given-names>LH</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Lieberburg</surname><given-names>IM</given-names></name><name><surname>Motter</surname><given-names>RN</given-names></name><name><surname>Mutter</surname><given-names>LC</given-names></name><name><surname>Nietz</surname><given-names>J</given-names></name><name><surname>Quinn</surname><given-names>KP</given-names></name><name><surname>Sacchi</surname><given-names>KL</given-names></name><name><surname>Seubert</surname><given-names>PA</given-names></name><name><surname>Shopp</surname><given-names>GM</given-names></name><name><surname>Thorsett</surname><given-names>ED</given-names></name><name><surname>Tung</surname><given-names>JS</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><etal/><article-title>Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain</article-title><source>J Neurochem</source><year>2001</year><volume>76</volume><fpage>173</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2001.00012.x</pub-id><pub-id pub-id-type="pmid">11145990</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Imbimbo</surname><given-names>BP</given-names></name><name><surname>Del Giudice</surname><given-names>E</given-names></name><name><surname>Colavito</surname><given-names>D</given-names></name><name><surname>D'Arrigo</surname><given-names>A</given-names></name><name><surname>Dalle Carbonare</surname><given-names>M</given-names></name><name><surname>Villetti</surname><given-names>G</given-names></name><name><surname>Facchinetti</surname><given-names>F</given-names></name><name><surname>Volta</surname><given-names>R</given-names></name><name><surname>Pietrini</surname><given-names>V</given-names></name><name><surname>Baroc</surname><given-names>MF</given-names></name><name><surname>Serneels</surname><given-names>L</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name><name><surname>Leon</surname><given-names>A</given-names></name><article-title>1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity</article-title><source>J Pharmacol Exp Ther</source><year>2007</year><volume>323</volume><fpage>822</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1124/jpet.107.129007</pub-id><pub-id pub-id-type="pmid">17895400</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Fleisher</surname><given-names>AS</given-names></name><name><surname>Raman</surname><given-names>R</given-names></name><name><surname>Siemers</surname><given-names>ER</given-names></name><name><surname>Becerra</surname><given-names>L</given-names></name><name><surname>Clark</surname><given-names>CM</given-names></name><name><surname>Dean</surname><given-names>RA</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Galvin</surname><given-names>JE</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Quinn</surname><given-names>JF</given-names></name><name><surname>Sherzai</surname><given-names>A</given-names></name><name><surname>Sowell</surname><given-names>BB</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Thal</surname><given-names>LJ</given-names></name><article-title>Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease</article-title><source>Arch Neurol</source><year>2008</year><volume>65</volume><fpage>1031</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1001/archneur.65.8.1031</pub-id><pub-id pub-id-type="pmid">18695053</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Bateman</surname><given-names>RJ</given-names></name><name><surname>Munsell</surname><given-names>LY</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Swarm</surname><given-names>R</given-names></name><name><surname>Yarasheski</surname><given-names>KE</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><article-title>Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo</article-title><source>Nat Med</source><year>2006</year><volume>12</volume><fpage>856</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1038/nm1438</pub-id><pub-id pub-id-type="pmid">16799555</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Bateman</surname><given-names>RJ</given-names></name><name><surname>Siemers</surname><given-names>ER</given-names></name><name><surname>Mawuenyega</surname><given-names>KG</given-names></name><name><surname>Wen</surname><given-names>G</given-names></name><name><surname>Browning</surname><given-names>KR</given-names></name><name><surname>Sigurdson</surname><given-names>WC</given-names></name><name><surname>Yarasheski</surname><given-names>KE</given-names></name><name><surname>Friedrich</surname><given-names>SW</given-names></name><name><surname>Demattos</surname><given-names>RB</given-names></name><name><surname>May</surname><given-names>PC</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><article-title>A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system</article-title><source>Ann Neurol</source><year>2009</year><volume>66</volume><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1002/ana.21623</pub-id><pub-id pub-id-type="pmid">19360898</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Brinkmalm</surname><given-names>G</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Westman-Brinkmalm</surname><given-names>A</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><article-title>An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid</article-title><source>Neurosci Lett</source><year>2006</year><volume>409</volume><fpage>215</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2006.09.044</pub-id><pub-id pub-id-type="pmid">17049739</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="other"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Price</surname><given-names>E</given-names></name><name><surname>Brinkmalm</surname><given-names>G</given-names></name><name><surname>Stiteler</surname><given-names>M</given-names></name><name><surname>Olsson</surname><given-names>M</given-names></name><name><surname>Persson</surname><given-names>R</given-names></name><name><surname>Westman-Brinkmalm</surname><given-names>A</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Simon</surname><given-names>AJ</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><article-title>A novel pathway for amyloid precursor protein processing</article-title><source>Neurobiol Aging</source><year>2009</year><comment> in press </comment></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Gustavsson</surname><given-names>MK</given-names></name><name><surname>Brinkmalm</surname><given-names>G</given-names></name><name><surname>Westman-Brinkmalm</surname><given-names>A</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><article-title>Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease</article-title><source>Neurodegener Dis</source><year>2009</year><volume>6</volume><fpage>258</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1159/000264639</pub-id><pub-id pub-id-type="pmid">19955704</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name><article-title>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">6610841</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Tran</surname><given-names>AJ</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Persson</surname><given-names>R</given-names></name><name><surname>Brinkmalm</surname><given-names>G</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Westman-Brinkmalm</surname><given-names>A</given-names></name><article-title>characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry</article-title><source>J Proteome Res</source><year>2007</year><volume>6</volume><fpage>4433</fpage><lpage>4439</lpage><pub-id pub-id-type="doi">10.1021/pr0703627</pub-id><pub-id pub-id-type="pmid">17927230</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Vandermeeren</surname><given-names>M</given-names></name><name><surname>Geraerts</surname><given-names>M</given-names></name><name><surname>Pype</surname><given-names>S</given-names></name><name><surname>Dillen</surname><given-names>L</given-names></name><name><surname>Van Hove</surname><given-names>C</given-names></name><name><surname>Mercken</surname><given-names>M</given-names></name><article-title>The functional gamma-secretase inhibitor prevents production of amyloid beta 1-34 in human and murine cell lines</article-title><source>Neurosci Lett</source><year>2001</year><volume>315</volume><fpage>145</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(01)02369-2</pub-id><pub-id pub-id-type="pmid">11716984</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Sharples</surname><given-names>RA</given-names></name><name><surname>Vella</surname><given-names>LJ</given-names></name><name><surname>Nisbet</surname><given-names>RM</given-names></name><name><surname>Naylor</surname><given-names>R</given-names></name><name><surname>Perez</surname><given-names>K</given-names></name><name><surname>Barnham</surname><given-names>KJ</given-names></name><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Hill</surname><given-names>AF</given-names></name><article-title>Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes</article-title><source>FASEB J</source><year>2008</year><volume>22</volume><fpage>1469</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1096/fj.07-9357com</pub-id><pub-id pub-id-type="pmid">18171695</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Hung</surname><given-names>AY</given-names></name><name><surname>Schlossmacher</surname><given-names>MG</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms</article-title><source>J Biol Chem</source><year>1993</year><volume>268</volume><fpage>3021</fpage><lpage>3024</lpage><pub-id pub-id-type="pmid">8428976</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Gowing</surname><given-names>E</given-names></name><name><surname>Roher</surname><given-names>AE</given-names></name><name><surname>Woods</surname><given-names>AS</given-names></name><name><surname>Cotter</surname><given-names>RJ</given-names></name><name><surname>Chaney</surname><given-names>M</given-names></name><name><surname>Little</surname><given-names>SP</given-names></name><name><surname>Ball</surname><given-names>MJ</given-names></name><article-title>Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>10987</fpage><lpage>10990</lpage><pub-id pub-id-type="pmid">8157623</pub-id></mixed-citation></ref></ref-list></back></article>